• News
  • SAN DIEGO
  • BioTech

Neurocrine surges on drug study results

Neurocrine Biosciences (Nasdaq: NBIX) said Monday that one of its experimental drugs helped reduce the symptoms of tardive dyskinesia, an illness that causes involuntary movements and spasms, in a mid-stage clinical trial.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!